Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-711-1 | CAS number: 148-24-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
OECD 422 (rat; male/female) NOAEL 200 mg/kg bw/day
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2010
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes
- Specific details on test material used for the study:
- - Molecular weight: 145.16
- Molecular formula: C9H7NO
- Appearance: Solid - Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Age at study initiation of dosing: 9 weeks old
- Recovery: 0, 400 mg/kg/day - Route of administration:
- oral: gavage
- Vehicle:
- other: methylcellulose solution
- Details on oral exposure:
- - Male: 42 days
- Female: 42 - 46 days (from 14 days before mating to day 4 of lactation) - Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- Control animals:
- yes, concurrent vehicle
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Male: Salivation (400 mg/kg/day)
Female: Salivation (400 mg/kg/day), Ptosis (400 mg/kg/day), Lacrimation (400 mg/kg/day), Soiled periurogenital fur (400 mg/kg/day) - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Male: Decrease in the body weight gain (400 mg/kg/day, tendency), Increase in the body weight gain (Recovery 400 mg/kg/day)
Female: Decrease in the body weight and body weight gain (400 mg/kg/day), Decrease in the body weight (Recovery 400 mg/kg/day, tendency), Increase in the body weight gain (Recovery 400 mg/kg/day, tendency) - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Female: Decrease in the food consumption (400 mg/kg/day)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Female: Increase in the MCV and Plt (400 mg/kg/day), Decrease in the RBC (400 mg/kg/day, tendency), Increase in the RET (400 mg/kg/day, tendency)
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Female: Decrease in the ALP (400 mg/kg/day), Decrease in the ALT (400 mg/kg/day), Increase in Cl (400 mg/kg/day), Decrease in the Alb (400 mg/kg/day), Decrease in the A/G (400 mg/kg/day, ten
dency), Increase in the T-Cho and Ca (Recovery 400 mg/kg/day), Decrease in Cl and gamma-GTP (Recovery 400 mg/kg/day) - Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Male: Decrease in K (200 and 400 mg/kg/day), Protein positive (400 mg/kg/day)
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Male: Salivation (200 and 400 mg/kg/day)
Female: Salivation (200 and 400 mg/kg/day), Decrease in the numbers of supported rearing (200 and 400 mg/kg/day), Decrease in the numbers of unsupported rearing (400 mg/kg/day) - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Male: Increase in the liver weight (Relative) (Recovery 400 mg/kg/day), Increase in the kidney weight (Absolute) (Recovery 400 mg/kg/day)
Female: Decrease in the thymus weight (Absolute and Relative) (400 mg/kg/day), Increase in the liver weight (Relative) (Recovery 400 mg/kg/day) - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Female: White mottle in the stomach (400 mg/kg/day), Red mottle in the large intestine (400 mg/kg/day)
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Female: Decrease in the incidence of vacuolar degeneration of hepatocyte (400 mg/kg/day), Erosion,
ulcer, polymorphonuclear cell infiltration and squamous hyperplasia in the forestomach (400 mg/kg/
day), Ulcer, polymorphonuclear cell infiltration and
regenerative epithelium in the glandular stomach, cecum and colon (400 mg/kg/day), Increased
extramedullary hematopoiesis in the spleen (400 mg/kg/day), Increased pigment deposition in the spl
een (Recovery 400 mg/kg/day), Atrophy of the thymus (400 mg/kg/day) - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- other: gastrointestinal disorder
- Key result
- Critical effects observed:
- no
- Conclusions:
- For males, the NOAEL was considered to be 200 mg/kg/day, because the tendency of suppression of body weight gain was observed in the 400 mg/kg group.
For females (dams) the NOAEL was considered to be 200 mg/kg/day, because the suppression of body weight gain, lower food consumption and gastrointestinal disorder were observed in the 400 mg/kg group. - Executive summary:
Quinolin-8-ol was studied for oral toxicity in rats according to the OECD Test Guideline 422 at doses of 0, 100, 200, and 400 mg/kg. In the repeated dose oral toxicity test, salivation was observed in the 200 and 400 mg/kg groups of both sexes. However, salivation was not considered to be the treatment-related toxic effect, because it was the slight and transitory change. On functional observation battery (FOB)
test, lower numbers of supported rearing were observed in female in the 200 and 400 mg/kg groups, but it was not considered to be treatment-related suppression on CNS because there were no effects
in other parameters. Body weight gain in males receiving 400 mg/kg tended to be lower than those in the control group. Body weight gain and food consumption in females receiving 400 mg/kg were lower
than those in the control group. On urinalysis of males, low potassium excretion was noted in the 200 and 400 mg/kg groups, the number of protein-positives was increased in the 400 mg/kg group during the
administration period. However, these changes were considered to be a minor toxicological implication, because there were no histopathological lesions about renal function at the end of the administration
period. Histopathological evaluation demonstrated some gastrointestinal disorder in females receiving 400 mg/kg. There were no treatment-related findings at the recovery period. Therefore, it was concluded
that body weight and food consumption changes, and gastrointestinal disorder were corrected during the recovery period.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- System:
- gastrointestinal tract
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the observations made of systemic toxicity of quinolin-8 -ol there is no need to classify the target substance for STOT-RE in accordance with the criteria of CLP regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.